论文部分内容阅读
目的探讨急性髓系白血病（ＡＭＬ）巨核细胞系抗原（ＭＫ）表达与临床、生物学特征的关系。方法采用流式细胞仪间接免疫荧光法对成人初治ＡＭＬ患者２１１例进行检测。结果２７例（１２８％）表达ＭＫ；ＡＭＬ亚型中以杂合急性白血病（ＨＡＬ）和急性单核细胞白血病（Ｍ５）表达最高，分别为４５．５％和２４．１％。ＭＫ表达与ＣＤ３４抗原、外周血高白细胞数、多药耐药糖蛋白（Ｐｇｐ）高度相关（Ｐ＜０．０５），与染色体核型无关。ＭＫ＋ＡＭＬ的完全缓解（ＣＲ）率为３３．３％，明显低于ＭＫＡＭＬ的７１９％。结论巨核细胞系抗原表达可能起源于较早期造血干细胞的恶性转化，可作为临床判断疗效及预后的参考指标之一。
Objective To investigate the relationship between the expression and clinical and biological characteristics of acute myeloid leukemia (AML) megakaryocyte cell lineage antigen (MK). Methods 211 cases of newly diagnosed adult AML patients were detected by flow cytometry indirect immunofluorescence. Results MK was expressed in 27 cases (12.8%). The highest expression of AML in heterozygous acute leukemia (HAL) and acute monocytic leukemia (M5) was 45.5% and 24.1%, respectively. MK expression was highly correlated with CD34 antigen, peripheral white blood cell count, and multi-drug resistant glycoprotein (P-gp) (P<0.05), but not with karyotype. The complete remission (CR) rate of MK+AML was 33.3%, which was significantly lower than 71.9% of MK-AML. Conclusion The antigen expression of megakaryocyte cell line may originate from the malignant transformation of hematopoietic stem cells at early stage. It can be used as one of the reference indexes to judge clinical efficacy and prognosis.